President of Biopharma Kostiantyn Yefymenko said that the construction of a laboratory complex is underway, where the total investment volume will amount to $8,5 million. Construction is planned to be completed by the end of the year. In addition, 4-5 plasma centers are being built, the number of such centers is $2,5 million.
According to him, in 2020 the company's turnover amounted to about $35 million, and in 2021 Biopharma plans to double this figure.
Yefymenko added that in 2020 Biopharma was engaged in the production of immunoglobulins. Also, the company conducted clinical studies, which showed that when using immunoglobulins, the body's survival rate in difficult cases of the disease is 4 times higher than without these drugs. Accordingly, the company increased the production of immunoglobulins by 60% and increased its share in the domestic market compared to export to 80%.
At the same time, Yefymenko believes that in the future the ratio of sales in the domestic market in relation to exports will be 60% to 40%. In his opinion, until 2025, to provide Ukrainian citizens with blood plasma-based drugs, the investing-in-ukraine/starting-business-in-ukraine/build-an-enterprise/" rel="dofollow">enterprise will process about 600 thousand liters of plasma per year.
The Biopharma group of companies includes Biopharma Invest LLC, Biopharma Plasma Invest LLC, Biopharma Plasma LLC, and FZ Biopharma LLC. The company annually produces about 200 thousand packages of drugs.